Bayer Cropscience Ag v. Dow Agrosciences LLC
728 F.3d 1324
Fed. Cir.2013Background
- Bayer CropScience owned the 401 patent claiming a recombinant gene with 2,4-D monooxygenase activity to confer herbicide resistance.
- Dow AgroSciences sells seeds with aad-1 and aad-12 dioxygenases that cleave 2,4-D similarly, though not using Bayer’s Figure 10 gene.
- Bayer argued that its broad functional term 2,4-D monooxygenase covers enzymes that cleave the 2,4-D side chain, including dioxygenases.
- The district court limited the claim to the ordinary meaning of monooxygenase and rejected Bayer’s broad construction, finding no infringement.
- Bayer sought review, contending the term should be read broadly to cover the claimed functional genus, despite only one disclosed gene.
- The Federal Circuit affirmed, holding Bayer’s broad construction invalid for ambiguity and 112(a) written-description concerns.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Proper construction of 'the biological activity of 2,4-D monooxygenase'? | Bayer argues for a broad functional reading. | Dow argues for the ordinary scientific meaning of monooxygenase tied to 2,4-D. | The court rejects Bayer’s broad construction; adopts the ordinary meaning. |
| Does Bayer’s broad scope render the claim invalid under 112(a)? | Broad 2,4-D side-chain cleavage function is adequately described by the Figure 10 gene. | Broad functional coverage is not supported by the written description. | Yes; the broad genus lacks sufficient written description, rendering it invalid. |
| Should the court construe leading to noninfringement be affirmed on that basis alone? | Dow challenges only Bayer’s proposed construction. | Dow relies on district court construction and alternative narrower scopes. | Yes; the court affirms non-infringement under the adopted construction. |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (textual analysis governs claim construction with context)
- Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (functional descriptions must be tied to structure or disclosures)
- Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997) (written description and enablement considerations in genetic material)
- Carnegie Mellon Univ. v. Hoffman-La Roche Inc., 541 F.3d 1115 (Fed. Cir. 2008) (functional descriptions may meet written description if correlated with structure)
- Univ. of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916 (Fed. Cir. 2004) (structural or functional disclosures in genetic material)
- Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956 (Fed. Cir. 2002) (functional characteristics tied to disclosed structure may meet written description)